Lineage Cell Therapeutics (LCTX) Assets (2010 - 2026)

Lineage Cell Therapeutics has reported Assets for 17 years, with the latest figure at $109.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 1.99% year-over-year to $109.5 million; the trailing twelve-month figure through Mar 2026 stood at $109.5 million (down 1.99% YoY), and the FY2025 full-year result was $112.6 million, down 0.56% from the prior year.
• Assets for Q1 2026 stood at $109.5 million, down from $112.6 million in the prior quarter.
• The five-year high for Assets was $144.5 million in Q1 2022, with the low at $89.6 million in Q3 2025.
• Historically, Assets has averaged $111.9 million across 5 years, with a median of $111.7 million in 2023.
• The largest YoY upside for Assets was 12.97% in 2022 against a maximum downside of 29.15% in 2022.
• Lineage Cell Therapeutics' Assets stood at $123.7 million in 2022, then retreated by 18.31% to $101.0 million in 2023, then climbed by 12.08% to $113.2 million in 2024, then fell by 0.56% to $112.6 million in 2025, then retreated by 2.71% to $109.5 million in 2026.
• The last three Assets figures came in at $109.5 million (Q1 2026), $112.6 million (Q4 2025), and $89.6 million (Q3 2025), per Business Quant data.